TEL-AVIV, Israel, Feb. 23, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill”
or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late
clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer,
today announced that its Annual Report on Form 20-F, containing audited financial statements for the year ended December 31, 2016,
as filed with the Securities and Exchange Commission on February 23, 2017, is available on its website (http://www.redhillbio.com). Shareholders may receive a hard copy of the annual report free of
charge upon request. This press release is being issued pursuant to NASDAQ Listing Rule 5250(d)(1)(C).
About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) is a specialty biopharmaceutical company headquartered in Israel, primarily
focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for
the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill has a U.S. co-promotion agreement with Concordia
for Donnatal®, a prescription oral adjunctive drug used in the treatment of IBS and acute
enterocolitis. RedHill’s clinical-stage pipeline includes: (i) RHB-105 - an oral combination
therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii)
RHB-104 - an oral combination therapy for the treatment of Crohn's disease with an ongoing first
Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis and QIDP status for Nontuberculous
Mycobacteria (NTM) infections; (iii) BEKINDA® (RHB-102) - a
once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an
ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to
Salix Pharmaceuticals, Ltd.; (v) YELIVA® (ABC294640) - a Phase II-stage,
orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal
indications; (vi) MESUPRON - a Phase II-stage first-in-class, orally-administered uPA inhibitor, targeting
gastrointestinal and other solid tumors and (vii) RIZAPORT® (RHB-103) - an oral thin film formulation
of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in
Germany in October 2015. More information about the Company is available at: www.redhillbio.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking
statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are
beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing,
preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance
its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the
extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory
approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the
manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the
Company’s ability to establish and maintain corporate collaborations; (vi) the Company's ability to acquire products approved for
marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the
interpretation of the properties and characteristics of the Company’s therapeutic candidates and of the results obtained with its
therapeutic candidates in research, preclinical studies or clinical trials; (viii) the implementation of the Company’s business
model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish
and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without
infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property
defaulting in their obligations to the Company; (xi) estimates of the Company’s expenses, future revenues, capital requirements and
the Company’s needs for additional financing; (xii) competitive companies and technologies within the Company’s industry; and
(xiii) the impact of the political and security situation in Israel on the Company's business. More detailed information about the
Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings
with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC
on February 23, 2017. All forward-looking statements included in this Press Release are made only as of the date of this Press
Release. We assume no obligation to update any written or oral forward-looking statements unless required by
law.
Company contact: Adi Frish Senior VP Business Development & Licensing RedHill Biopharma +972-54-6543-112 adi@redhillbio.com IR contact (U.S.): Marcy Nanus Senior Vice President The Trout Group +1-646-378-2927 Mnanus@troutgroup.com
